Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
Eli Lilly reported mid-stage trial results for EloraTZP, a combination of the amylin asset eloralintide and the approved obesity drug Zepbound. In adults with obesity and type 2 diabetes, the regimen delivered a weight loss of 23.3 percent compared to 14.8 percent for tirzepatide alone. The therapy also achieved greater A1C reduction than tirzepatide 15 mg. The combination swept primary and secondary endpoints in the Phase 2 trial. However, the higher reduction in weight came with an increased rate of treatment discontinuation due to gastrointestinal side effects. Eli Lilly plans to launch a Phase 3 trial before the end of the year.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Eli Lilly's EloraTZP combines eloralintide and tirzepatide.
- ✓ The Phase 2 trial of adults with obesity and type 2 diabetes showed 23.3 percent weight loss for the combination versus 14.8 percent for tirzepatide alone.
- ✓ EloraTZP delivered greater weight loss and A1C reduction compared to tirzepatide 15 mg.
- ✓ Eli Lilly intends to start a Phase 3 trial before the end of the year.
What changed
Eli Lilly announced mid-stage trial results showing its new amylin and Zepbound combination drug, EloraTZP, outperformed tirzepatide alone in adults with obesity and type 2 diabetes.
Live updates
-
Eli Lilly Reports Strong Results for Amylin-Zepbound Obesity Combo
Eli Lilly reported mid-stage trial results for EloraTZP, a combination of the amylin asset eloralintide and the approved obesity drug Zepbound. In adults with obesity and type 2 diabetes, the regimen delivered a weight loss of 23.3 percent compared to 14.8 percent for tirzepatide alone. The therapy also achieved greater A1C reduction than tirzepatide 15 mg. The combination swept primary and secondary endpoints in the Phase 2 trial. However, the higher reduction in weight came with an increased rate of treatment discontinuation due to gastrointestinal side effects. Eli Lilly plans to launch a Phase 3 trial before the end of the year.
Why it matters
The new data follows other major developments in weight-loss medications, including trial results for Lilly's retatrutide GLP-1 and reports of patients losing up to 60 pounds on the company's treatments. The pharmaceutical company continues to advance advanced combination regimens targeting better blood sugar control and higher weight loss thresholds. These mid-stage results position the amylin-tirzepatide combination for advanced clinical testing as the company seeks to build upon the success of its existing portfolio.
What is confirmed
- Eli Lilly's EloraTZP combines eloralintide and tirzepatide.
- The Phase 2 trial of adults with obesity and type 2 diabetes showed 23.3 percent weight loss for the combination versus 14.8 percent for tirzepatide alone.
- EloraTZP delivered greater weight loss and A1C reduction compared to tirzepatide 15 mg.
- Eli Lilly intends to start a Phase 3 trial before the end of the year.
Still unconfirmed
- Gastrointestinal side effects led to a higher rate of patients stopping treatment during the trial.
What to watch next
- Launch of the Phase 3 clinical trial before the end of the year
- Further safety and discontinuation data from extended trials
confidence 100%Sources used for this update (12)
- The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
- NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- CNBC — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Eli Lilly — Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
- USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
- Fierce Biotech — Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
- Yahoo — EASD 2026: Lilly’s amylin-tirzepatide combo beats its weight loss drug alone
- www.medicaldaily.com — Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 D....
- www.careyounews.org — 차세대 비만 신약을 젭바운드와 병용한 중기 임상, 제2형 당뇨병 환자 체중 평균 23.3퍼센트 감소
- www.biospace.com — Superior weight loss, blood sugar control propel Lilly’s ...
- www.prnewswire.com — Lilly's EloraTZP (combination of eloralintide and tirzepatide ...
- joeymed.com — EloraTZP in 2026: Lilly's Amylin-Tirzepatide Combo Posts 23% ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community